J
John L. Berk
Researcher at Boston University
Publications - 168
Citations - 11571
John L. Berk is an academic researcher from Boston University. The author has contributed to research in topics: Amyloidosis & Transthyretin. The author has an hindex of 39, co-authored 150 publications receiving 8751 citations. Previous affiliations of John L. Berk include Boston Medical Center.
Papers
More filters
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Julian D. Gillmore,Mathew S. Maurer,Rodney H. Falk,Giampaolo Merlini,Thibaud Damy,Angela Dispenzieri,Ashutosh D. Wechalekar,John L. Berk,John L. Berk,Candida Cristina Quarta,Martha Grogan,Helen J. Lachmann,Sabahat Bokhari,Adam Castano,Sharmila Dorbala,Geoff B. Johnson,Andor W. J. M. Glaudemans,Tamer Rezk,Marianna Fontana,Giovanni Palladini,Paolo Milani,P.L Guidalotti,Katarina Flatman,Thirusha Lane,Frederick W. Vonberg,Carol J. Whelan,James C. Moon,Frederick L. Ruberg,Frederick L. Ruberg,Edward J. Miller,David F. Hutt,Bouke P. C. Hazenberg,Claudio Rapezzi,Philip N. Hawkins +33 more
TL;DR: Bone scintigraphy enables the diagnosis of cardiac ATTR amyloidosis to be made reliably without the need for histology in patients who do not have a monoclonal gammopathy, and proposes noninvasive diagnostic criteria that are applicable to the majority of patients with this disease.
Journal ArticleDOI
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson,Márcia Waddington-Cruz,John L. Berk,Michael Polydefkis,Peter J. Dyck,Annabel K. Wang,Violaine Planté-Bordeneuve,Fabio Barroso,Giampaolo Merlini,Laura Obici,Morton A. Scheinberg,Thomas H. Brannagan,William J. Litchy,Carol J. Whelan,Brian M. Drachman,David C. Adams,Stephen B. Heitner,Isabel Conceição,Hartmut H. Schmidt,Giuseppe Vita,Josep M. Campistol,Josep Gamez,Peter D. Gorevic,Edward Gane,Amil M. Shah,Scott D. Solomon,Brett P. Monia,Steven G. Hughes,Jesse Kwoh,Bradley W. McEvoy,Shiangtung W. Jung,Brenda F. Baker,Elizabeth J. Ackermann,Morie A. Gertz,Teresa Coelho +34 more
TL;DR: Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis and improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.
Journal ArticleDOI
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
Martha Skinner,Vaishali Sanchorawala,David C. Seldin,Laura M. Dember,Rodney H. Falk,John L. Berk,Jennifer J. Anderson,Carl O'Hara,Kathleen T. Finn,Caryn A. Libbey,Janice F. Wiesman,Karen Quillen,Niall Swan,Daniel G. Wright +13 more
TL;DR: Analysis of consecutive patients with AL amyloidosis from 6 separate trials over 8 years shows that high-dose intravenous melphalan therapy combined with autologous stem-cell transplantation greatly improves duration of survival and ameliorates organ dysfunction.
Journal ArticleDOI
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk,Ole B. Suhr,Laura Obici,Yoshiki Sekijima,Steven R. Zeldenrust,Taro Yamashita,Michael A. Heneghan,Peter D. Gorevic,William J. Litchy,Janice F. Wiesman,Erik Nordh,Manuel Corato,Alessandro Lozza,Andrea Cortese,Jessica Robinson-Papp,Theodore Colton,Denis Rybin,Alice Bisbee,Yukio Ando,Shu-ichi Ikeda,David C. Seldin,Giampaolo Merlini,Martha Skinner,Jeffery W. Kelly,Peter J. Dyck +24 more
TL;DR: Among patients with familial amyloid polyneuropathy, the use of diflunisal compared with placebo for 2 years reduced the rate of progression of neurological impairment and preserved quality of life.